Oruka Therapeutics, Inc. Investment Income, Interest
Oruka Therapeutics, Inc. (ORKA) reported Investment Income, Interest of $8.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-10
- Oruka Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $8.90M, a 130.67% increase year-over-year.
- Oruka Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $4.61M, a 12.56% increase year-over-year.
- Oruka Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $4.85M.
- Oruka Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $3.83M, a 188.12% increase year-over-year.
- Oruka Therapeutics, Inc. investment income, interest for fiscal 2025 was $16.63M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 8 month | Investment Income, Interest 9 month | Investment Income, Interest 11 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.90M 10-Q · filed 2026-08-10 | $13.50M 10-Q · filed 2026-08-10 | $18.35M derived: sum of 3 quarters · filed 2026-08-10 | $22.18M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $4.61M 10-Q · filed 2026-05-13 | $9.46M derived: sum of 2 quarters · filed 2026-05-13 | $13.29M derived: sum of 3 quarters · filed 2026-05-13 | $17.14M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $8.68M derived: sum of 2 quarters · filed 2026-03-12 | $12.54M derived: sum of 3 quarters · filed 2026-08-10 | $16.63M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $3.83M 10-Q · filed 2025-11-12 | $7.69M derived: sum of 2 quarters · filed 2026-08-10 | $11.78M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $3.86M 10-Q · filed 2026-08-10 | $7.95M 10-Q · filed 2026-08-10 | ||||
| 2025-03-31 | $4.09M 10-Q · filed 2026-05-13 | |||||
| 2024-12-31 | $5.86M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $1.33M 10-Q · filed 2025-11-12 | $1.33M 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |